ExoPTEN For Acute Glaucoma
Regenerate, Rewire, Recovery
The Unmet Medical Need
ExoPTEN: Regenerating Nerves, Recovering Function
Presented at ARVO 2025
A-left side-normal, B-middle-damaged, C-right side-after treatment
- Minimally Invasive treatment showed functional restoration of damaged optic nerve to healthy levels in animals which lead to 75% functional recovery.
- Optical Nerve Crush (ONC) – a Glaucoma animal model, mimic the Glaucoma nerve damage
Multibillion Dollar Market
The estimated global annual incidence of acute angle-closure glaucoma (AACG) ranges from approximately 355,000 to 700,000 cases. This estimation accounts for regional variations in incidence rates and population distributions.
These figures underscore the significant global health burden posed by AACG and highlight the potential market for therapies aimed at preventing or mitigating vision loss associated with this condition.
Estimated Global Market for Vision-Preserving Acute Glaucoma Therapies
Socioeconomic represents indirect costs including lost productivity, assistive services and mobility, quality of life reductions.
References:
1. Chan et al., 2022
2. Wittenborn & Rein, 2021
Preclinical Studies at Sheba Medical Center
A large scale preclinical study on laboratory animals is underway at Sheba Medical Center together with the Goldschleger Eye Institute
